These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15075115)

  • 1. Amifostine feasibility and efficacy in autologous stem cell transplantation for multiple myeloma.
    Stocchi R; Damiani D; Masolini P; Michelutti A; Baccarani M; Tosi P; Fanin R
    Haematologica; 2004 Apr; 89(4):ELT02. PubMed ID: 15075115
    [No Abstract]   [Full Text] [Related]  

  • 2. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.
    Thieblemont C; Dumontet C; Saad H; Roch N; Bouafia F; Arnaud P; Hequet O; Espinouse D; Salles G; Roy P; Eljaafari-Corbin A; Du Manoir-Baumgarten C; Coiffier B
    Bone Marrow Transplant; 2002 Dec; 30(11):769-75. PubMed ID: 12439700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases.
    Kornacker M; Luft T; Ho AD; Schaefer HJ
    Eur J Haematol; 2005 Mar; 74(3):250-3. PubMed ID: 15693795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients.
    Jantunen E; Kuittinen T; Nousiainen T
    Leuk Lymphoma; 2002 Oct; 43(10):1961-5. PubMed ID: 12481892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tandem autologous stem cell transplantation for multiple myeloma: is it applicable and effective outside clinical trials?
    Dimopoulos MA
    Haematologica; 2005 Dec; 90(12):1588. PubMed ID: 16330425
    [No Abstract]   [Full Text] [Related]  

  • 7. Trial of amifostine in autologous stem cell transplant.
    Sastry P; Bhagwat R; Biswas G; Khadwal A; Narayanan P; Bakshi A; Parikh P
    Bone Marrow Transplant; 2006 Jan; 37(1):117-8. PubMed ID: 16273114
    [No Abstract]   [Full Text] [Related]  

  • 8. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
    Vela-Ojeda J; García-Ruiz-Esparza MA; Padilla-González Y; Gómez-Almaguer D; Gutiérrez-Aguirre CH; Gómez-Rangel D; Morales-Toquero A; Ruiz-Delgado GJ; Delgado-Lamas JL; Ruiz-Argüelles GJ
    Ann Hematol; 2007 Apr; 86(4):277-82. PubMed ID: 17262193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuing erythropoietin during peripheral blood stem cell collection in myeloma: can it reduce toxicity of autologous transplants?
    Labonté L; Iqbal T; McDiarmid S; Bence-Bruckler I; Huebsch L; Allan D
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):132-3. PubMed ID: 18158970
    [No Abstract]   [Full Text] [Related]  

  • 11. New strategies in transplantation therapy.
    Harousseau JL
    Oncology (Williston Park); 2004 Nov; 18(13):1614-5, 1617. PubMed ID: 15648294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Kuendgen A; Fenk R; Bruns I; Dommach M; Schutte A; Engers R; Hünerlitürkoglu A; Haas R; Kobbe G
    Bone Marrow Transplant; 2006 Jul; 38(1):69-70. PubMed ID: 16715114
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft.
    Fujikawa K; Nakaseko C; Cho R; Abe D; Oda K; Tanaka H; Ohwada C; Ozawa S; Takeuchi M; Sakaida E; Shimizu N; Naito M; Nishimura M; Saito Y
    Bone Marrow Transplant; 2007 Nov; 40(10):997-9. PubMed ID: 17724437
    [No Abstract]   [Full Text] [Related]  

  • 14. The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
    Ozdogu H; Boga C; Kizilkilic E; Kozanoglu I; Karakus S; Sahin FI; Unalan D; Haberal M
    Transplant Proc; 2007 May; 39(4):1257-60. PubMed ID: 17524948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophagocytic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma; successful treatment with high-dose intravenous immunoglobulin.
    Ostronoff M; Ostronoff F; Coutinho M; Calixto R; Souto Maior AP; Sucupira A; Florencio R; Tagliari C
    Bone Marrow Transplant; 2006 Apr; 37(8):797-8. PubMed ID: 16518425
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma.
    Murakami H; Fujii H; Inaba T; Shimazaki C; Okamoto S; Miwa A; Sawamura M; Abe M; Chou T; Asaoku H; Kitahara Y; Hayashi K; Kosaka M; Togawa A; Takatsuki K;
    Eur J Haematol; 2004 Sep; 73(3):169-73. PubMed ID: 15287913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
    Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T
    Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma.
    Wiesmann A; Einsele H; Kanz L; Dohmen BM
    Bone Marrow Transplant; 2005 Jul; 36(1):89-90. PubMed ID: 15895113
    [No Abstract]   [Full Text] [Related]  

  • 19. A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
    Carella AM; Beltrami G; Corsetti MT; Scalzulli P; Carella AM; Musto P
    Haematologica; 2004 Dec; 89(12):1534-6. PubMed ID: 15590410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.
    Haas PS; Bauchmüller K; Kühnemund A; Finke J; Ihorst G; Engelhardt M
    Ann Hematol; 2006 Mar; 85(3):191-3. PubMed ID: 16365747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.